Alcon AG — MarketDX

ALC.SW2

Alcon prices €500M senior notes offering

Alcon has priced a €500 million senior notes offering with a 3.875% annual interest rate, maturing in 2033. The notes will be issued by Alcon Finance and fully guaranteed by Alcon on a senior basis. The offering is expected to close on September 2, 2026, and the proceeds will be used for general corporate purposes, including potentially refinancing existing debt. The notes are expected to be listed on the Luxembourg Stock Exchange and traded on its Euro MTF market.

ALC.SW

Seeking Alpha·10hRead more ▾

ALC.SW▼

Glaukos Shares Surge 67.9% Year to Date on iDose TR and Epioxa Momentum

Glaukos shares have surged 67.9% year to date, significantly outperforming its industry's 8.4% decline and the S&P 500's 12% return, driven by accelerating operating momentum from the commercial ramp of iDose TR and the early launch of Epioxa. Second-quarter revenues jumped 49.5% to $185.6 million, prompting management to raise 2026 revenue guidance by $60-$65 million to $680-$700 million. U.S. glaucoma revenues increased 64% to $118.5 million, with iDose TR sales reaching approximately $74 million, up 37% sequentially, while the Corneal Health franchise grew 48% to $30.4 million, including roughly $11 million from Epioxa. The company is expanding internationally, with second-quarter international revenues up 17% to $36.6 million, and is advancing a diversified pipeline across five novel therapeutic platforms and 13 publicly disclosed programs. Key risks include reimbursement execution for iDose TR, early-stage Epioxa commercialization, and competitive pressures from Alcon, Sight Sciences, and AbbVie.

GKOS ▲ALC.SW ▼SGHT ▼

Zacks Investment Research·6dRead more ▾

Biotech & Genomic Medicine▲

Alcon and RxSight Enter Strategic Collaboration on Adjustable Intraocular Lenses

Alcon Inc. and RxSight, Inc. announced on July 6 a non-exclusive strategic collaboration to co-develop post-operatively adjustable pseudophakic intraocular lenses, pairing RxSight's light-adjustable technology with Alcon's global commercial footprint and surgical equipment portfolio. The partnership validates RxSight's technology while expanding Alcon's premium lens offerings. In Q1 2026, Alcon reported net sales of $2.7 billion, up 10% year-over-year, with core diluted earnings per share of $0.85 and a new $1.5 billion share repurchase program, while RxSight posted revenue of $30.9 million, down 18.5% year-over-year, and a net loss of $15.9 million, or $0.38 per share, while reiterating full-year revenue guidance of $120 million to $135 million. Alcon also opened its second training center in partnership with the Aravind Eye Care System in India on July 24. Hedge fund ownership of Alcon rose to 46 funds in Q1 2026 from 44 in Q4 2025, while RxSight remained at 33 funds.

RXST ▲ALC.SW ▲

Biotech & Genomic Medicine ▲

Insider Monkey·13dRead more ▾

ALC.SW▲5

Alcon Q2 2026 Sales Rise 7%, Raises EPS Outlook on Strong Equipment and IOL Demand

Alcon Inc reported 7% sales growth in the second quarter of 2026, driven by broad-based strength across its surgical and vision care franchises. Unity VCS equipment sales surged 25% year-over-year with higher-than-expected average selling prices, while Panoptix Pro IOL adoption exceeded expectations, representing roughly 90% of Panoptix implants. Core operating margin expanded 160 basis points to 20.6%, and the company raised its full-year constant-currency EPS growth outlook to 12% to 15%. However, implantables growth remained subdued at 1%, with IOLs up only 2% amid competitive launches and flat US cataract procedure volumes. Alcon also discontinued its Power Vision IOL program due to performance issues and announced a collaboration with RxSight for next-generation adjustable lenses.

ALC.SW ▲RXST ▲

GuruFocus·15dRead more ▾

ALC.SW▲

RxSight Withdraws 2026 Guidance After Revenue Decline and Alcon Deal

RxSight has withdrawn its full-year 2026 financial guidance as it pivots strategy following a 19% year-over-year drop in product sales and a new collaboration with Alcon. Second-quarter total revenue reached $33.7 million, including $6.5 million from the Alcon partnership, while product sales excluding that collaboration fell to $27.2 million. Light Adjustable Lens unit volumes declined 9% to 24,917, and gross margin excluding Alcon revenue slipped to 71.2% from 74.9% a year earlier. The company reported a net loss of $12.1 million, or $0.29 per share, and ended the quarter with approximately $209 million in cash and short-term investments, plus a $60 million upfront payment from Alcon received after the quarter closed. President and CEO Aziz Mottiwala said the guidance withdrawal allows a thorough business assessment without prior constraints, with formal guidance expected to resume in early 2027.

RXST ▼ALC.SW ▲

GuruFocus·21dRead more ▾

ALC.SW▲

RxSight Fair Value Drops to $8.43 After Soft Q2 and Guidance Cut

RxSight's modelled fair value has been lowered from $9.93 to $8.43 following softer second-quarter trends and a guidance cut. Jefferies reduced its price target from $7.50 to $6.50 with a Hold rating, while BofA cut its target from $8 to $6.50 and maintained an Underperform rating after preliminary Q2 sales of $27 million missed the $32 million Street expectation and 2026 guidance was reduced by $13 million at the midpoint. The revised valuation also reflects a shift in assumed revenue growth from 5.22% to 8.76%, a lower expected net profit margin from 12.79% to 11.76%, a future P/E multiple moving from 26.74x to 22.78x, and a discount rate easing from 7.85% to 7.45%. Analysts noted competitive trialing, macro pressures, and utilization at a four-year low, though BofA highlighted that the new Alcon collaboration could expand RxSight's reach into light adjustable PCIOLs over the longer term.

RXST ▼ALC.SW ▲

Simply Wall St·32dRead more ▾

ALC.SW▲2

RxSight projects 2026 revenue of $140M to $160M, including $30M to $40M from Alcon collaboration

RxSight has revised its full-year 2026 revenue outlook to a range of $140 million to $160 million, which includes $30 million to $40 million from its newly announced strategic collaboration with Alcon. The company's standalone RxSight sales are now expected to be $110 million to $120 million, reflecting the continuation of headwinds experienced in the second quarter. Preliminary second-quarter total company revenue is approximately $32 million to $34 million, with $5 million to $7 million attributed to the Alcon agreement, while standalone sales of roughly $27 million fell 20% year-over-year. Management attributed the slowdown to widespread competitive trialing activity and pressured consumer sentiment, and it plans to accelerate U.S. sales force investments to reengage accounts. Full-year gross margin guidance was raised to 73% to 75% due to a favorable product mix, while operating expenses are still expected at the high end of $150 million to $160 million.

RXST ▼ALC.SW ▲

Seeking Alpha·50dRead more ▾

ALC.SW▲2

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

Alcon and RxSight have entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses. The partnership combines RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs to create a co-developed technology that enables surgeons to fine-tune visual outcomes after cataract surgery. Under the agreement, RxSight will receive a $60 million upfront payment and could earn up to an additional $140 million in development and regulatory milestone payments. Alcon will lead global commercialization, while RxSight will handle development and manufacturing and receive royalties on net sales.

ALC.SW ▲RXST ▲

Business Wire·51dRead more ▾

ALC.SW▼

Alcon's New Platforms and Dry Eye Momentum Offset by Macro and Competitive Headwinds

Alcon's new surgical platforms and lenses are gaining adoption, and dry eye momentum is expected to support growth, but adverse macroeconomic conditions and intense competition remain concerns. The company reported share gains in U.S. AT-IOLs and is preparing to launch an upgraded Vivity lens in early 2027, while continuing to scale Tryptyr and Systane in dry eye and broaden its contact lens lineup with TOTAL30 and PRECISION7. However, incremental tariffs in the United States and China totaled $33 million in the first quarter of 2026, creating a 120 basis points drag on core gross margin, and competition is intensifying outside the United States. The Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $3.48 over the past 30 days, with revenues pegged at $11.06 billion, suggesting a 7.2% rise from the prior year. Alcon stock has dipped 25.1% over the past year, compared with a 10.4% decline for the industry and a 23.9% rise for the S&P 500.

ALC.SW ▼

Zacks Investment Research·55dRead more ▾

ALC.SW▼

Johnson & Johnson invests over $1 billion in Jacksonville vision expansion

Johnson & Johnson is spending more than $1 billion to expand its Vision manufacturing, packaging, and distribution facilities in Jacksonville, Florida. The expansion is part of a broader $55 billion U.S. investment initiative focused on manufacturing and R&D. The Jacksonville site will scale domestic production capacity for ACUVUE contact lenses using advanced manufacturing technologies. The commitment deepens the company's presence in eye care, where it competes with Alcon and Bausch + Lomb, and may tighten quality control while reducing exposure to global logistics issues.

JNJ ▲ALC.SW ▼BLCO ▼

Simply Wall St·65dRead more ▾